Given that RUNX1 causes hematological malignancies mainly through somatic mutations and functions as a tumor suppressor, RUNX1 is more promising as a target for the treatment of solid tumors, where it is a tumor-promoting gene, with the exception of breast and liver cancers. Here, RUNX1 is linked to neoplasm.